Neoadjuvant chemotherapy response influences outcomes in non‐colorectal, non‐neuroendocrine liver metastases.
Published: 12th June 2018
Authors: A. M. Lucchese, A. N. Kalil, A. Ruiz, V. Karam, O. Ciacio, G. Pittau et al.
Indications for surgical resection of non‐colorectal, non‐neuroendocrine (NCNNE) liver metastases are unclear. This study analysed the influence of response to neoadjuvant chemotherapy and the presence of extrahepatic disease (EHD) on outcomes.
Patients who underwent hepatic resection for NCNNE liver metastases and who received neoadjuvant chemotherapy at a single centre between 1982 and 2016 were analysed retrospectively. Patients were classified as having no EHD, controlled EHD or non‐controlled EHD.
Hepatic resection was performed in 199 patients (81·2 per cent) after partial or complete response to chemotherapy or disease stabilization, and 46 patients (18·8 per cent) after tumour progression. Patients with progressive disease after chemotherapy had worse overall survival than those without (23
The prognosis of patients with NCNNE liver metastases is influenced by preoperative chemotherapy and resectability.Full text
You may also be interested in
Authors: B. Groot Koerkamp, W. R. Jarnagin
Validation of at least 1 mm as cut‐off for resection margins for pancreatic adenocarcinoma of the body and tail.
Authors: T. Hank, U. Hinz, I. Tarantino, J. Kaiser, W. Niesen, F. Bergmann et al.
Notes: Validating 1mm for R0
Development and validation of a difficulty score to predict intraoperative complications during laparoscopic liver resection.
Authors: M. C. Halls, G. Berardi, F. Cipriani, L. Barkhatov, P. Lainas, S. Harris et al.
Notes: Helps improve selection for laparoscopic liver resection
Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. BJS 2018; 105: 946-958.
Authors: E. Versteijne, J. A. Vogel, M. G. Besselink, O. R. C. Busch, J. W. Wilmink, J. G. Daams et al.
Notes: Improved survival with neoadjuvant treatment
Authors: G. A. Margonis, K. Sasaki, S. Gholami, Y. Kim, N. Andreatos, N. Rezaee et al.
Notes: Predicts survival
Reappraisal of classification of distal cholangiocarcinoma based on tumour depth. BJS 2018; 105: 867-875.
Authors: H. Aoyama, T. Ebata, M. Hattori, M. Takano, H. Yamamoto, M. Inoue et al.
Notes: Better for T staging
Prediction of major complications after hepatectomy using liver stiffness values determined by magnetic resonance elastography.
Authors: N. Sato, A. Kenjo, T. Kimura, R. Okada, T. Ishigame, Y. Kofunato et al.
Notes: liver stiffness predicts complications
Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases.
Authors: M. Okuno, C. Goumard, T. Mizuno, S. Kopetz, K. Omichi, C.‐W. D. Tzeng et al.
Notes: Bad sign of advanced disease
Randomized clinical trial
Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy. BJS 2018; 105: 811-819.
Authors: M. Schindl, R. Függer, P. Götzinger, F. Längle, M. Zitt, S. Stättner et al.
Notes: Not effective in reducing complications
Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. BJS 2018; 105: 857-866.
Authors: X.‐F. Zhang, J. Chakedis, F. Bagante, Q. Chen, E. W. Beal, Y. Lv et al.
Notes: Lymphadenectomy is important
Meta‐analysis of an artery‐first approach versus standard pancreatoduodenectomy on perioperative outcomes and survival. BJS 2018; 105: 628-636.
Authors: N. Ironside, S. G. Barreto, B. Loveday, S. V. Shrikhande, J. A. Windsor, S. Pandanaboyana et al.
Notes: Benefits to artery‐first approach
Authors: A. Ito, T. Ebata, Y. Yokoyama, T. Igami, T. Mizuno, J. Yamaguchi et al.
Notes: Ethanol ablation is effective